Past events

Dr. Reddy’s and Sindusfarma are hosting a joint webinar which aims to discuss Sartans - a new class of mutagenic impurities discovered in drugs commonly used to treat hypertension, heart and kidney diseases.

Mike Burns will be speaking at this event on behalf of Lhasa Limited.

A avaliação do risco de acordo com ICH Q3D é obrigatória para a submissão de pedidos de registro de produtos farmacêuticos à Anvisa, de modo a garantir a segurança dos pacientes no que diz respeito à contaminação por impurezas elementares.

Earlier this year the OECD published test guideline 497, which describes how to combine New Approach Methodologies within a defined approach to replace the use of animal testing when assessing skin sensitisation. One of the three approved defined approaches in the guideline, ITSv1 by Kao, includes Lhasa's in silico expert knowledge tool Derek Nexus as a required information source.

In this seminar, professionals from Lhasa Limited and Kang Yusheng will evaluate the application of Lhasa's solutions to meet the ICH M7 guidelines, and will explain how to deal with impurities based on a large amount of toxicological knowledge provided by Derek and Sarah Nexus, using case studies.

At the 2021 Toxicology Forum Virtual Summer Meeting Dr. David Ponting, Lhasa Senior Scientist will be chairing a session on Monday 2nd August titled, N-Nitrosamine Impurities in Pharmaceuticals - Potency, Prediction, and Acceptable Limits.

In this virtual event we investigated the new ANVISA guidance for N-Nitrosamines with presentations from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa representatives.

Join Lhasa Limited Senior Scientist, Andrew Thresher, Principal Business Analyst, Simon Gayton, and Principal Global Alliance Manager, Will Drewe, for an insight and overview of Lhasa's Carcinogenicity database (LCDB).

We were delighted to welcome Andrew Teasdale PhD to present within this webinar; Why you should consider controlling your potentially mutagenic impurities outside the lab.

Andrew is currently the chair of AstraZeneca’s Impurity Advisory Board and has a wealth of knowledge developed over the last 20 years of working within the pharmaceutical industry. He is a leading AZ expert for a number of key impurity areas, including mutagenic impurities (MIs).

The International Workshop on (Quantitative) Structure-Activity Relationships in Environmental and Health Sciences is taking place as a virtual event in June 2021. We are delighted that both Dr. Adrian Fowkes and Dr. David Ponting will be virtually presenting poster summaries of their recent work.

Drug Discovery Chemistry is a virtual event focused on discovery and optimization challenges of small molecule drug candidates.

During this event Dr. Adrian Fowkes will be presenting a poster - Effiris: Improving in silico secondary pharmacology profiling using federated QSAR models.

Dr. Anax Oliveira - Head of Toxicology at Lhasa Limited - presented at the International Akademie Fresenius Conference "QSAR and Read-Across in Toxicological Assessments" in April 2021 on the topic of 'Current application of in silico tools for genotoxicity assessment'.

Dr. Susanne Stalford, Senior Scientist at Lhasa Limited, will be presenting at SOT on Thursday 18th March 2021.

Susanne will be presenting within the morning session on the topic of 'Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk'.

Lhasa Senior Scientist, Dr. Susanne Stalford is presenting as part of this webinar series - on the use of new approach methodologies (NAMs) in risk assessment - on the development of an adverse outcome pathway (AOP) network to support an integrated approach to testing and assessment of carcinogenicity risk.

Effiris delivers state-of-the-art secondary pharmacology models, where each model has had the opportunity to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - leveraging the breadth of available high-quality proprietary data.

Dr. Anax Oliveira, Head of Toxicology at Lhasa Limited, will be presenting at the ANSES Symposium on Tuesday 26^th January 2021. Anax will be presenting within the ‘Computational and predictive methods for risk assessment: issues and promises’ session.

Join Lhasa Limited Senior Scientist, David Wilkinson and Principal Global Alliance Manager, William Drewe as they discuss Lhasa's AI/PDE data sharing project.

Lhasa Limited Senior Scientist, Dr. Susanne Stalford will be presenting and also a panellist at the toxicology forum, a virtual workshop event in December. The topic of the event is Assessing Carcinogenicity: Hazard Identification, Classification, and Risk Assessment. 

At this virtual event Lhasa Scientist, Dr. Steven Kane be sharing a presentation titled ‘Application of Adverse Outcome Pathways (AOPs) to Support a Genotoxicity Assessment’.

Lhasa Limited is pleased to be hosting an AOP themed virtual symposium made up of a series of 4 webinars.

Select the link below to read more about each of the sessions.

Principal Scientist, Dr. Donna Macmillan will be presenting a poster on Dermal Sensitisation Thresholds during this online event.

In this webinar, Dr. Robert Foster, Lhasa Limited Scientist will present on Lhasa’s new ICH M7 expert review functionality, which now offers automated arguments within Nexus based on specific Derek and Sarah predictions.

In this webinar, Lhasa Limited Senior Scientists Dr. Rachael Tennant and Dr. David Ponting will discuss the mutagenic effects of nitrosamines, and the correlation with carcinogenic potential. Including, describing trends in the structure-activity and structure-potency relationships of these compounds that can be determined from available data, and how this can be used to improve in silico prediction models.

This upcoming nitrosamine webinar aims to provide an overview of the risk of nitrosamines within drug substance synthesis.

This webinar series aims to provide an overview of the key features of Lhasa’s software, illustrate how the software can help with toxicity hazard assessments and explain how it can be used to meet key regulations.

We think you will be interested in attending if; you work in the life sciences industry, in toxicology, chemistry or regulatory affairs and/or, you are curious about how Lhasa’s software can accelerate drug development and hazard assessment.

We're delighted to be attending the 2020 Society of Toxicology 59th Annual Meeting and ToxExpo, in Anaheim, California.

We will have many activities, including posters and Exhibitor-Hosted Sessions at this year's SOT. 

The recording for this webinar is now available. 

Join Lhasa, regulators from ANVISA and representatives from the pharmaceutical industry for our free two day symposium.

This event is now full. If you are still interested in attending, please register for the waitlist and a place will be offered to you in the case of a delegate cancelling their registration.

Este evento tem lotação esgotada. Contudo se está interessado em participar reserve o seu lugar na lista de espera será contactado no caso de desistência de algum participante.

Lhasa has been holding International Collaborative Group Meetings since its inception, and on the 14^th March we will be holding our 51^st event in Baltimore.

An initial agenda can be found below. Register now!

Join us for this free to attend 1-day event to find out more about the ICH M7 guideline.

The ICH M7 Roadshow is a free 1-day event featuring:

• Presentations

• Interactive workshop

• Industry networking experience

• An opportunity to ask questions

The event will cover an introduction to ICH M7 and provide an overview of Derek, Sarah and Vitic and how they facilitate ICH M7 guidelines.

Attending the event will be Lhasa Sales Manager Sian Ives and Lhasa Senior Account Manager Dave Yeo.

Join Scientist Dr Michael Burns for this webinar on the development of Mirabilis including a case study. 

Three Lhasa Scientists will present an overview of four posters from the 2018 SOT 57^th Annual Meeting and ToxExpo.

Taking place in San Antonio on the 15^th March, 2018, our next ICGM will follow the SOT 57^th Annual Meeting. View the agenda and register for free now. 

Held in Basel, Switzerland on the 11^th October 2017,  slides from this event can be found by clicking on "More info".

Lhasa Limited will be attending the 53rd Congress of the European Societies of Toxicology which is to be held in Bratislava, Slovakia.

An exciting programme is being prepared with over "30 symposia and workshops that will highlight the novel findings in the field of toxicology".

Sales Executives, Harry Proctor and Alison Reeves will be exhibiting at this event and will be available at booth number 19. Also attending the event is Account Manager Dave Yeo, and Scientists Martin Payne and Rob Foster. 

This Joint Pharmaceutical Analysis Group are holding a symposium to 'explore the role of Mass Spectrometry (MS)' in identifying various impurities that can be found.

Dr Martin Ott, Principal Scientist at Lhasa Limited, has been invited to speak at this event: 

In Silico Predictive Approaches to Degradation using Zeneth

Harry Proctor, Sales Executive, will be exhibiting at this event alongside Andrew Shannon-Little, Account Manager.

The 46^th International Collaborative Group Meeting was held in Baltimore, Maryland on the 16^th March 2017.  

View the presentations now!

Lhasa Limited European ICGM

The 44^th Lhasa Limited ICGM took place at the Roche Innovation Center in Basel, Switzerland, on the 13^th October 2016.  

Featured presentations included: 

• Derek and Sarah for Web
• Intuitive Model Building with Sarah Nexus
• Lhasa Limited Collaborative Data and Knowledge Sharing Projects
• Mirabilis - The Scientific Future
• Product Update 44th ICGM
• Setaria - Future Plans
• Skin Sensitisation - Negative Predictions, Validations and Integrated Testing Strategies
• Theoretical Purge Argumentation for Genotoxic Impurities
• An Intelligent Knowledge Organisation Solution
• eTOXsys - Highly Relevant Proprietary Data and Predictive Models for Drug Development

View the presentations now!

The EUROTOX annual meetings offer a great opportunity for networking and remaining up-to-date with all of the cutting-edge research happening in this "challenging and expanding discipline". 

The programme includes workshops, symposia, poster sessions and lectures from Keynote speakers. For more information, visit the event website. 

Krishan Patel, Sian Ives and David Yeo, from Lhasa Limited's Member services team, will be attending this event, visit them at booth 58!   

Dr. Will Drewe, Business Development Manager is also attending, and will be presenting a poster: 

eTOXsys - An Integrated Platform for Profiling And Data Mining Across Multiple Databases and Prediction Models